A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Have one of the following solid tumor cancers:

• Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small celllung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervicalcancer (squamous cell carcinoma), head and neck squamous cell carcinoma orprostate cancer

• Cohort A2/B1/B2: urothelial carcinoma

• Cohort C1: triple negative breast cancer

• Cohort C2: non-small cell lung cancer

• Cohort C3: ovarian or fallopian tube cancer

• Cohort C4: cervical cancer

• Cohort C5: head and neck squamous cell carcinoma

• Prior Systemic Therapy Criteria:

• Cohort A1/C1-5: Individual has received all standard therapies for which theparticipant was deemed to be an appropriate candidate by the treatinginvestigator; OR there is no standard therapy available for the disease. Thereis no restriction on number of prior therapies

• Cohort A2/B1/B2: Individual must have received at least one prior regimen inthe advanced or metastatic setting. There is no restriction on number of priortherapies.

• Prior enfortumab vedotin specific requirements:

• Cohorts A1/A2/C1-5: prior treatment with enfortumab vedotin is allowed, but notrequired

• Cohort B1: individual must be enfortumab vedotin naive in theadvanced/metastatic setting

• Cohort B2: individual must have received enfortumab vedotin in themetastatic/advanced setting.

• Measurability of disease

• Cohort A1: measurable or non-measurable disease as defined by ResponseEvaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)

• Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Have adequate archival tumor tissue sample available or undergo a screening biopsyif allowed per country specific regulations

Exclusion Criteria:

• Individual with known or suspected uncontrolled CNS metastases

• Individual with uncontrolled hypercalcemia

• Individual with uncontrolled diabetes

• Individual with evidence of corneal keratopathy or history of corneal transplant

• Any serious unresolved toxicities from prior therapy

• Significant cardiovascular disease

• Current of history of intestinal obstruction in the previous 3 months

• Recent thromboembolic event or bleeding disorder

• Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms

• History of pneumonitis/interstitial lung disease

• History of Grade ≥3 skin toxicity when receiving enfortumab vedotin

• Individuals who are pregnant, breastfeeding or plan to breastfeed during study orwithin 30 days of last dose of study intervention

• Individual with active uncontrolled infection